Advertisement

C-reactive protein levels and subsequent cancer outcomes: Results from a prospective cohort study

      Abstract

      Chronic inflammation has been implicated in the pathogenesis of many common chronic diseases, including cancer. C-reactive protein (CRP) concentration is a non-specific serum marker of inflammation, and higher levels have been observed among individuals who go on to develop cardiovascular disease. Nested case-control studies were conducted within the CLUE II study, a community-based cohort, to examine the association between CRP concentrations and subsequent development of colorectal or prostate cancer. CRP concentrations were higher among individuals who went on to develop colon cancer, but not rectal or prostate cancer, compared with controls. The association between CRP concentrations and development of colon cancer is consistent with other evidence suggesting a role of inflammation and cancer. Preventive interventions that decrease systemic chronic inflammation have the potential to reduce certain types of cancer as well as cardiovascular disease. However, the potential benefits of anti-inflammatory chemopreventive agents must be weighed against their adverse effects before widespread use is recommended.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rifai N.
        • Tracy R.P.
        • Ridker P.M.
        Clinical efficacy of an automated high-sensitivity C-reactive protein assay.
        Clin Chem. 1999; 45: 2136-2141
        • Ridker P.M.
        • Cushman M.
        • Stampfer M.J.
        • Tracy R.P.
        • Hennekens C.H.
        Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
        N Engl J Med. 1997; 336 ([Erratum: N Engl J Med 1997;337:356): 973-979
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        N Engl J Med. 2000; 342: 836-843
        • Erlinger T.
        • Platz E.
        • Rifai N.
        • Helzlsouer K.J.
        C-reactive protein and the risk of incident colorectal cancer.
        JAMA. 2004; 291: 585-590
        • Platz E.
        • DeMarzo A.
        • Erlinger T.
        • et al.
        No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostrate cancer.
        Prostate. 2004; 59: 393-400
      1. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. C-reactive protein (CRP) and colorectal cancer incidence in a cohort of male smokers.Proceedings Frontiers in Cancer Prevention, Baltimore, MD, October 2005.

        • Il’yasova D.
        • Colbert L.H.
        • Harris T.B.
        • et al.
        Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 2413-2418
      2. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality, an individual participant meta-analysis. JAMA 2005;294:1799–809.

        • Zhang S.M.
        • Buring J.E.
        • Lee I.M.
        • Cook N.R.
        • Ridker P.M.
        C-reactive protein levels are not associated with increased risk for colorectal cancer in women.
        Ann Intern Med. 2005; 142: 425-432
        • Ito Y.
        • Suzuki K.
        • Tamakoshi K.
        • et al.
        Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC study.
        J Epidemiol. 2005; : S185-S189
        • Thun M.J.
        • Namboodiri M.M.
        • Calle E.E.
        • Flanders W.D.
        • Heath Jr., C.W.
        Aspirin use and risk of fatal cancer.
        Cancer Res. 1993; 53: 1322-1327
        • Chan A.T.
        • Giovannucci E.L.
        • Meyerhardt J.A.
        • Schernhammer E.S.
        • Curhan G.C.
        • Fuchs C.S.
        Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.
        JAMA. 2005; 294: 914-923
        • Baron J.A.
        • Cole B.F.
        • Sandler R.S.
        • et al.
        A randomized trial of aspirin to prevent colorectal adenomas.
        N Engl J Med. 2003; 348: 891-899
        • Sandler R.S.
        • Halabi S.
        • Baron J.A.
        • et al.
        A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
        N Engl J Med. 2003; 348: 883-890
        • Sturmer T.
        • Glynn R.J.
        • Lee I.M.
        • Manson J.E.
        • Buring J.E.
        • Hennekens C.H.
        Aspirin use and colorectal cancer: post-trial follow-up data from the physicians’ health study.
        Ann Intern Med. 1998; 128: 713-720
        • Cook N.R.
        • Lee I.M.
        • Gaziano J.M.
        • et al.
        Low-dose aspirin in the primary prevention of cancer. The women’s health study: a randomized controlled trial.
        JAMA. 2005; 294: 47-55
        • Brown J.R.
        • DuBois R.N.
        COX-2: a molecular target for colorectal cancer prevention.
        J Clin Oncol. 2005; 23: 2840-2855
        • Drazen J.M.
        COX-2 inhibitors – a lesson in unexpected problems.
        N Engl J Med. 2005; 352: 1131-1132
        • Psaty B.M.
        • Furberg C.D.
        COX-2 inhibitors-lessons in drug safety.
        N Engl J Med. 2005; 352: 1133-1135
        • Solomon S.D.
        • McMurray J.J.V.
        • Pfeffer M.A.
        • et al.
        Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
        N Engl J Med. 2005; 352: 1071-1080
        • Bresalier R.S.
        • Sandler R.S.
        • Quan H.
        • et al.
        Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
        N Engl J Med. 2005; 352: 1092-1102
        • Schatzkin A.
        Intermediate markers as surrogate endpoints in cancer research.
        Hematol Oncol Clin North Am. 2000; 14: 887-905
        • Winawer S.J.
        Natural history of colorectal cancer.
        Am J Med. 1999; 106: 3S-6S
        • Kim E.C.
        • Lance P.
        Colorectal polyps and their relationship to cancer.
        Gastroenterol Clin North Am. 1997; 26: 1-17
      3. Colorectal Cancer Fact Sheet. Available from: http://www.cdc.gov/colorectalcancer/what_cdc_is_doing/about_cdc_program.htm.

        • Fisher B.
        • Costantino J.P.
        • Wickerman D.L.
        • et al.
        Tamoxfen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
        J Natl Cancer Inst. 1998; 90: 1371-1388
        • McQuay H.J.
        • Moore R.A.
        Using numerical results from systematic reviews in clinical practice.
        Ann Intern Med. 1997; 126: 712-720
      4. Aspirin for the primary prevention of cardiovascular events: summary of the evidence. Article originally in Annals of Internal Medicine 2002. Rockville, MD: Agency for Healthcare Research and Quality. Available from: http://www.ahrq.gov/clinic/ 3rduspstf/aspirin/aspsum1.htm.

        • Brewster A.M.
        • Christo D.K.
        • Lai H.
        • Helzlsouer K.
        Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
        Cancer. 2005; 103: 1147-1153